New study aims to unlock secrets of rare muscle disease
NCT ID NCT04792931
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is building a library of information and samples from 60 adults with suspected autoimmune myopathy, a rare muscle disease. Researchers will collect blood, urine, stool, and muscle tissue, along with medical data, to better understand the condition. The goal is to improve diagnosis and future treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could improve understanding of autoimmune myopathies and help develop better diagnostic tools or treatments in the future.
- What could go wrong
- This is an observational study, not a treatment trial. It is small (60 participants) and only at one hospital, so findings may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2022
- Expected to finish
-
May 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Clinical suspicion of Adult Inflammatory Myopathy * Social security affiliation Exclusion Criteria: * Pregnant and lactating women * Patients unable to consent * Patients refusing to participate in the research. * Patients under legal protection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Idiopathic inflammatory myopathies are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU de BREST
RECRUITINGBrest, 29200, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ease muscle weakness in myositis?
- Can a One-Time cell therapy reset the immune system in autoimmune disease?
- Immune clues in the blood may foretell heart trouble
- Can a simple blood test unlock the secrets of brain autoimmune diseases?
- Engineered immune cells take aim at Hard-to-Treat muscle disease
- Engineered immune cells take aim at childhood autoimmune diseases